MAPK7: Potential Drug Target Or Biomarker (G5598)

Target Name: MAPK7

NCBI ID: G5598

MAPK7

MAPK7: Potential Drug Target Or Biomarker

MAPK7 (Mammalian Arginine Prolyl Hydroxylase 7) is a protein that is expressed in various tissues of the body, including muscle, heart, and brain. It is a key enzyme in the arginine/prolyl cycle, a process that is involved in the production of nitric oxide, a signaling molecule that regulates blood flow and blood pressure.

MAPK7 is a protein that is often used as a drug target or biomarker because of its role in the arginine/prolyl cycle. The arginine/prolyl cycle is a critical pathway for the production of nitric oxide, which helps to relax blood vessels and increase blood flow to the body's tissues. This is important for maintaining a healthy blood pressure and for delivering oxygen and nutrients to the body's tissues.

MAPK7 is a protein that is expressed in the heart, muscle, and brain, and it is involved in the production of nitric oxide. It is a key enzyme in the arginine/prolyl cycle, and it is the rate-limiting step in the production of nitric oxide. This means that if MAPK7 is inhibited, the production of nitric oxide will be reduced, which can lead to a decrease in blood flow and a rise in blood pressure.

MAPK7 is also involved in the regulation of cell signaling pathways. It has been shown to be involved in the regulation of Angiotensin-converting enzyme (ACE) activity, which is a enzyme that is involved in the production of angiotensin, a hormone that causes blood vessels to constrict and blood pressure to rise.MAPK7 has also been shown to be involved in the regulation of the Notch signaling pathway, which is involved in the regulation of cell growth and differentiation.

MAPK7 is a protein that has been shown to be involved in a number of different signaling pathways. It is a potential drug target or biomarker because of its role in the arginine/prolyl cycle and its involvement in cell signaling pathways. Additionally, MAPK7 is a good candidate for a biomarker to diagnose cardiovascular disease, as its levels have been shown to be decreased in patients with cardiovascular disease.

In conclusion, MAPK7 is a protein that is expressed in various tissues of the body and is involved in the arginine/prolyl cycle, which is critical for the production of nitric oxide. It is a potential drug target or biomarker, due to its role in cell signaling pathways and its involvement in the regulation of the Notch signaling pathway. Additionally, MAPK7 is a good candidate for a biomarker to diagnose cardiovascular disease. Further research is needed to fully understand the role of MAPK7 in the arginine/prolyl cycle and its potential as a drug target or biomarker.

Protein Name: Mitogen-activated Protein Kinase 7

Functions: Plays a role in various cellular processes such as proliferation, differentiation and cell survival. The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction

The "MAPK7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPK7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets